Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation.

ABSTRACT: Activating mutations in the estrogen receptor (ER) α-gene (ESR1) result in constitutive transcriptional activity in the absence of estrogen and are associated with endocrine resistance in metastatic ER-positive (+) breast cancer. It is not known how activating ESR1 mutations may alter the predictive values of molecular imaging agents for endocrine therapy response. This study investigated the effect of an activating ESR1 mutation on pretreatment ¹⁸F-fluoroestradiol (¹⁸F-FES) uptake and early assessment of endocrine therapy response using ¹⁸F-FDG and ¹⁸F-fluorofuranylnorprogesterone (¹⁸F-FFNP) PET/CT imaging of tumor glucose metabolism and progesterone receptor (PR) expression, respectively. Methods: ER+, PR+

SUBMITTER: Kumar M 

PROVIDER: S-EPMC8049365 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature